Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Ewing Sarcoma Therapeutics Pipeline Analysis, 2017

P&S Market Research-Ewing sarcoma Therapeutics Pipeline Analysis report

Ewing Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments

Published: April 2017
Report Code: LS11014
Available Format: pdf
Pages: 94

Pipeline Overview

Ewing sarcoma is a condition in which formation of cancer or tumor takes place in the bones and soft tissues. It is the second most common type of primary sarcoma found in young adults and children. Ewing sarcoma occurs in ribs, long bones, spine (vertebral column) and pelvis. The prevalence of Ewing sarcoma has increased in the past few years, but the exact cause of the disease is still unknown; some of the risk factors that increase the probability of occurrence of Ewing sarcoma include genetic changes (translocation between the chromosomes), age, gender (Ewing sarcoma is more common in males as compared to females), ethnicity (Ewing sarcoma is more commonly found in white people as compared to black people in the U.S.). According to the American Cancer Society, it is estimated that around 30 children in the U.S. get affected with Ewing sarcoma every year. Ewing sarcoma is a very severe form of cancer that occurs among the children aged between 10 to15 years of age. The disease can be easily diagnosed through magnetic resonance imaging scan, CT scan, positron emission tomography scan and biopsy. Some of the symptoms associated with Ewing sarcoma includes pain as well as swelling in chest, back, legs, pelvis and arms, fever, bone fracture, weight loss, loss of appetite, fatigue and malaise.

Pipeline Analysis

Ewing sarcoma pipeline contains large number of small molecule.




Competitive Landscape

Some of the key players developing Ewing sarcoma therapeutics include Pfizer Inc., Merrimack Pharmaceuticals, Celldex therapeutics, and others.

Scopefor Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Epidemiology Forecast - Epidemiology analysis and forecast
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment